Computational Drug Design of Natural Product-Based Azole Hybrids for Multifactorial Diseases: Success Stories

Complex diseases such as cancer, neurodegenerative disorders, and metabolic syndromes involve multiple interconnected biological pathways, often rendering single-target therapies ineffective. Conventional drugs frequently lead to undesirable side effects and contribute to Multidrug Resistance (MDR). Natural products, known for their structural diversity and relatively lower toxicity, have emerged as promising candidates for the development of multi-target therapeutic agents. Hybrid molecules, which combine pharmacophores from natural and synthetic origins, offer a novel strategy to simultaneously modulate multiple disease pathways. This review systematically compiles and analyzes studies on hybrid molecules derived from natural products with potential multi-target activity. Relevant literature was selected from scientific databases (PubMed, Scopus, Web of Science), and key hybrid scaffolds were examined with respect to design strategy, molecular docking performance, pharmacokinetic properties, and biological activity. Several classes of natural product-based hybrid molecules, such as triazoles, imidazoles, and tetrazoles, demonstrated effective binding to multiple disease-related targets. Computational studies revealed favorable binding energies and drug-like properties. Many of these hybrids showed potential to overcome MDR and improve therapeutic outcomes in preclinical studies. The reviewed hybrid molecules exhibit promising polypharmacological properties for treating multifactorial diseases. Their design often leverages the inherent bioactivity of natural products while enhancing selectivity and potency through synthetic modification. While encouraging, the findings remain primarily computational or in early-stage experimentation, and thus require further validation. Natural product-derived hybrid molecules represent a promising frontier in the development of multi-target therapies for complex diseases. Future research should focus on experimental validation, pharmacokinetic profile optimization, and in vivo efficacy studies. This approach may lead to the next generation of safer, more effective therapeutic agents.